Patent · US Active

Anti-DLL3 antibody drug conjugates and methods of use

US9155803B1 · kind B1 · utility

8Cited by
46References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 8, 2015
Grant dateOct 13, 2015
Priority date
Expiry dateJun 8, 2035

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/70596
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat tumors having neuroendocrine features are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.